| Chimeric antigen receptor T cells in refractory B-cell lymphomas SJ Schuster, J Svoboda, EA Chong, SD Nasta, AR Mato, Ö Anak, ... New England Journal of Medicine 377 (26), 2545-2554, 2017 | 1792 | 2017 |
| Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation JN Kochenderfer, ME Dudley, RO Carpenter, SH Kassim, JJ Rose, ... Blood, The Journal of the American Society of Hematology 122 (25), 4129-4139, 2013 | 711 | 2013 |
| Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis AM Petrich, M Gandhi, B Jovanovic, JJ Castillo, S Rajguru, DT Yang, ... Blood, The Journal of the American Society of Hematology 124 (15), 2354-2361, 2014 | 537 | 2014 |
| Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic … A Chanan-Khan, P Cramer, F Demirkan, G Fraser, RS Silva, S Grosicki, ... The Lancet Oncology 17 (2), 200-211, 2016 | 521 | 2016 |
| Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial JC Byrd, P Hillmen, P Ghia, AP Kater, A Chanan-Khan, RR Furman, ... Journal of clinical oncology 39 (31), 3441-3452, 2021 | 465 | 2021 |
| Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis AR Mato, C Nabhan, MC Thompson, N Lamanna, DM Brander, B Hill, ... Haematologica 103 (5), 874, 2018 | 436 | 2018 |
| Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial JA Jones, AR Mato, WG Wierda, MS Davids, M Choi, BD Cheson, ... The lancet oncology 19 (1), 65-75, 2018 | 428 | 2018 |
| Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study S O'Brien, JA Jones, SE Coutre, AR Mato, P Hillmen, C Tam, A Österborg, ... The Lancet Oncology 17 (10), 1409-1418, 2016 | 403 | 2016 |
| Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study AR Mato, NN Shah, W Jurczak, CY Cheah, JM Pagel, JA Woyach, ... The Lancet 397 (10277), 892-901, 2021 | 397 | 2021 |
| Outcomes of COVID-19 in patients with CLL: a multicenter international experience AR Mato, LE Roeker, N Lamanna, JN Allan, L Leslie, JM Pagel, K Patel, ... Blood, The Journal of the American Society of Hematology 136 (10), 1134-1143, 2020 | 312 | 2020 |
| Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients AR Mato, BT Hill, N Lamanna, PM Barr, CS Ujjani, DM Brander, C Howlett, ... Annals of Oncology 28 (5), 1050-1056, 2017 | 266 | 2017 |
| Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience AR Mato, C Nabhan, PM Barr, CS Ujjani, BT Hill, N Lamanna, ... Blood, The Journal of the American Society of Hematology 128 (18), 2199-2205, 2016 | 216 | 2016 |
| The Addition of the BTK inhibitor Ibrutinib to anti-CD19 chimeric antigen receptor T cells (CART19) improves responses against mantle cell lymphoma M Ruella, SS Kenderian, O Shestova, JA Fraietta, S Qayyum, Q Zhang, ... Clinical Cancer Research 22 (11), 2684-2696, 2016 | 200 | 2016 |
| Front‐line, dose‐escalated immunochemotherapy is associated with a significant progression‐free survival advantage in patients with double‐hit lymphomas: a systematic review … C Howlett, SJ Snedecor, DJ Landsburg, J Svoboda, EA Chong, ... British journal of haematology 170 (4), 504-514, 2015 | 189 | 2015 |
| Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States AR Mato, M Thompson, JN Allan, DM Brander, JM Pagel, CS Ujjani, ... Haematologica 103 (9), 1511, 2018 | 170 | 2018 |
| Outcomes of patients with double-hit lymphoma who achieve first complete remission DJ Landsburg, MK Falkiewicz, J Maly, KA Blum, C Howlett, T Feldman, ... Journal of Clinical Oncology 35 (20), 2260-2267, 2017 | 169 | 2017 |
| Mechanisms of resistance to noncovalent Bruton’s tyrosine kinase inhibitors E Wang, X Mi, MC Thompson, S Montoya, RQ Notti, J Afaghani, ... New England Journal of Medicine 386 (8), 735-743, 2022 | 159 | 2022 |
| COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia LE Roeker, DA Knorr, MC Thompson, M Nivar, S Lebowitz, N Peters, ... Leukemia 35 (9), 2703-2705, 2021 | 151 | 2021 |
| Long-term outcomes from a randomized dose optimization study of chimeric antigen receptor modified T cells in relapsed chronic lymphocytic leukemia NV Frey, S Gill, EO Hexner, S Schuster, S Nasta, A Loren, J Svoboda, ... Journal of Clinical Oncology 38 (25), 2862-2871, 2020 | 151 | 2020 |
| Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial TD Shanafelt, XV Wang, CA Hanson, EM Paietta, S O’Brien, J Barrientos, ... Blood, The Journal of the American Society of Hematology 140 (2), 112-120, 2022 | 150 | 2022 |